Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This updated edition is a great reference for anyone working in multinational product development and marketing.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 11 January 2017 | By Zachary Brennan
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) on Wednesday released its agenda of new and revised draft guidance documents to be published this calendar year, and it includes several eagerly-awaited documents, such as ones on biosimilar interchangeability (which has been on the list since 2015) and a revision of a draft on postmarket safety reporting for drugs and biologics.
The 102 draft guidance documents slated for release in 2017 are on par with the number expected in 2016 (also 102 draft documents), but up significantly from the 60 guidance documents from 2013 and about 70 from 2014, and as in previous years, the largest chunk of new draft guidances will be procedural.
CDER plans to release 28 procedural draft guidelines in 2017, including ones on refuse to file issues with new drug application and biologics license applications, as well as several related to Risk Evaluation and Mitigation Strategies.
On the quality/chemistry manufacturing and controls (CMC) front, new drafts are expected on CMC postapproval manufacturing changes for specified biologics in annual reports, visual inspection of injectable drugs and in-vitro methods for the evaluation of abuse-deterrent properties of opioids.
As far as drafts that will be revised in 2017, FDA points to 27 documents (up from 21 revisions planned for 2016), including nine that were included on both the 2016 and 2017 lists, including:
Guidance Agenda: New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2017
Tags: interchangeability, FDA guidance, guidance agenda, CDER guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.